Kerendia · DIN 02531925 · 20 mg · tablet
Limited Use, Reason for Use code 700 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 700 required
Write on scriptReason for Use code 700 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 700
Reason for Use code 700
For use as an adjunct to standard-of-care (SOC) therapy in adult patients diagnosed with BOTH chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of end-stage kidney disease and a sustained decrease in estimated
glomerular filtration rate (eGFR), and cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in patients who meet the following criteria:
1. 18 years of age or older; AND
2. Diagnosed with CKD with an eGFR level greater than or equal to 25mL/min/1.73 square metres AND an albuminuria level greater than or equal to 30mg/g (or 3mg/mmol); AND
3. Patient is also diagnosed with T2D; AND
4. Finerenone is prescribed in addition to standard-of-care (SOC)* therapy for patients diagnosed with CKD with comorbid T2D; AND
* SOC therapy is defined as maximally tolerated doses of angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy in combination with a sodium-glucose cotransporter-2 (SGLT2) inhibitor unless SGLT2 inhibitors are contraindicated or not tolerated.
5. Patient does not have a diagnosis of chronic heart failure (CHF) with reduced ejection fraction and persistent symptoms meeting New York Heart Association Class II to IV; AND
6. Patient is not using finerenone in combination with another mineralocorticoid receptor antagonist (MRA); AND
7. Finerenone is prescribed in consultation with a nephrologist or other clinician with experience in the diagnosis and management of patients with CKD and T2D.
Discontinuation Criteria:
Patients meeting the initiation criteria and started on finerenone should be discontinued on treatment if the patient's eGFR is less than 15mL/min/1.73 square metres and/or if the urinary albumin-to-creatinine ratio (UACR) has increased from baseline level after starting treatment with finerenone.
Approved Dosage:
Up to 20mg once daily as per the product monograph
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Kerendia · DIN 02531925
Manufacturer: Bayer Inc., Health Care Division; listing date 2024-03-28
Health Canada: Marketed since 2022-11-22 · brand KERENDIA · ATC C03DA05 FINERENONE · form Tablet · route Oral · ingredients FINERENONE 20 MG · company Bayer inc · schedule Prescription
Kerendia: Formulary list price $3.26 per unit (the source does not state the unit; exact figure $3.2565). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531925)
Source record
DIN 02531925: Kerendia
Raw flags: sec12=Y, sec3=Y
Item: 243220002; group id 376; item number 0897; lccId 00386; manufacturer id BAH
Source form: Tab; strength: 20mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.2565; ministry $3.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531925
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102101
Shortage status: not checked (no credentials)